CClinicalTrials.gg
RecruitingNCT07487155JUSTICE-TDAHUpdated Aug 11, 2026

Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Disorder

An interventional study of Workshop in Attention Deficit Disorder With Hyperactivity (ADHD) and Substance Use Disorder (SUD), sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by University Hospital, Brest · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Better identification of ADHD in vulnerable people with SUD is essential to improving their care. This project aims to provide appropriate support for this at-risk population.

02

Conditions studied

  • Attention Deficit Disorder With Hyperactivity (ADHD)
  • Substance Use Disorder (SUD)
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult, under the supervision of the justice system or monitored by a correctional facility
  • Diagnosis of Substance Use Disorder (SUD)
  • Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
  • No objection from the patient
  • Affiliated with a Social Security system

Exclusion criteria

Exclusion Criteria:

  • Severe or decompensated psychiatric disorders
  • Severe cognitive impairment
  • Lack of understanding of the French language
  • Refusal to participate
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Workshops

    Workshops with a small group of patients.

    Other: Workshop

Interventions

  • OtherWorkshop

    Assess the 5 workshops, co-constructed by the scientific committee and thanks to feedback from the qualitative study

05

What researchers measure

Primary outcomes

  1. 80% of patients participated in the workshops

    The primary outcome measure is the acceptability of the program to participants in the pilot workshops, gathered through: * Semi-structured pre- and post-intervention interviews * A Likert scale * Workshop participation rate (at least 80%)

    Time frame: From enrollment to the end of wordshop at 6 months

Secondary outcomes

  1. SF-12 quality of life

    The secondary outcome measure will be measured by the SF-12 quality of life, before and after the 5 workshops. The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life.

    Time frame: From enrollment to the end of wordshop at 6 months

06

Study locations

1 of 1 sites recruiting
  • CHU Brest
    Brest, 29200, France
    • Morgane GUILLOU LANDREAT, MD · Contact · morgane.guillou@chu-brest.fr · 029822342348
    • Morgane GUILLOU LANDREAT, MD · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — All collected data that underlie results in a publication

Supporting information: Study protocol

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07487155
Lead sponsor
University Hospital, Brest
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Aug 3, 2026
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Marie BARAIS, MD
Contact
marie.barais@gmail.com
+332 98 01 64 02
Morgane GUILLOU-LANDREAT, MD
principal investigator · CHU Brest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion